The processes of intraepithelial migration, intraluminal seeding, and field cancerization as models for initiation, spread, and recurrences of urothelial cell carcinoma are reviewed in light of recent molecular investigations. The accumulated molecular data on synchronous and metachronous tumors indicate that the majority of recurrent and multiple tumors are monoclonal. Molecular data has also shown the presence of chromosomal and genetic changes in precursor lesions as well as in normal urothelial cells. Genetic-histological mapping of cystectomized bladders has shown that overt tumors occur as local events in areas of genetically altered urothelium. A model is put forward in which the tumor process is initiated by genetically altered but histologically normal cells that produce fields of altered cells by intraepithelial displacement. By the accumulation of further genetic changes the fields of altered urothelium reaches a state of criticality which locally may produce frank tumors.
Urothelial cell carcinoma
Urothelial cell carcinomas (UCC) originate from the epithelial cells of the inner lining of the bladder wall. Seventy percent of the tumors are papillary and confined to the urothelial mucosa (stage Ta) or to the lamina propria (stage T1) whereas the remaining invade the muscle (T2), perivesical fat (T3) or surrounding organs (T4) (Figure 1 ). It is not uncommon for patients with Ta/T1 tumors to show multiple, synchronous tumors. Most Ta tumors are of low grade (G1 or G2), rarely progress, and are associated with a favorable prognosis whereas high grade Ta (TaG3) and T1 tumors represent a significant risk of tumor progression. Carcinoma in situ, Tis, is a flat lesion commonly found in association with malignant tumors and is generally believed to be the precursor of invasive cancer.
UCC is characterized by a number of chromosomal and genetic alterations. Cytogenetic loss and loss of heterozygosity (LOH) of chromosome 9 is particularly frequent occurring in 40-50% of the cases [1, 2] . The most commonly lost region in 9p includes CDKN2A that frequently also shows homozygous losses. Several regions of chromosome arm 9q have been suggested to harbor tumor suppressor genes but no definite gene has so far been identified [2] . The receptor gene FGFR3 is activated by mutations in up to 70% of the Ta tumors but less frequently in invasive tumors [3] . The reverse pattern is seen for TP53. This has led to the suggestion that UCC may constitute two entities of tumors developing through two different genetic pathways [4] . Superficial tumors, Ta and T1, are mostly treated by transurethral resection, in many cases combined with subsequent intravesical chemo-or immunotherapy. However, up to 70% of the patients show recurrences after treatment making a lifelong follow-up by regular cystoscopy necessary. Patients with muscle-invasive disease are commonly treated by cystectomy sometimes accompanied by systemic neo adjuvant or adjuvant chemotherapy.
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The biology of UCC gives an opportunity to investigate the early stages of tumor development as both recurrences and multiple tumors frequently are available. This makes it possible to study "reinitiation" of the transforming process in the same genetic and environmental background.
Furthermore, the topology of the bladder organ has made it feasible to analyze non-cancerous tissue in a systematic way. In the present review the data on genetic changes in normal, premalignant, as well as in synchronous and metachronous UCC tumors will be examined. Suggested hypotheses for the origin of synchronous and metachronous tumors will be evaluated in view of the existing data and possible alternative explanations will be put forward taking the recent findings of cancer stem cells into consideration.
Intraepithelial migration, intraluminal seeding, and field cancerization
Two major hypotheses have been proposed to explain the origin of synchronous and metachronous tumors in patients with UCC ( Figure 2 ). One assumes a monoclonal origin either through intraepithelial migration of tumor cells or by intraluminal seeding from a primary carcinoma. The second, the field cancerization model, proposes a field change and that individual cells in these fields are transformed to overt tumors and states, in the stronger version, that independent genetic events will produce multiple or recurrent tumors. In this scenario the genomic changes in neighboring cells will be unrelated and the resulting tumors consequently oligoclonal. In the original version [5] , however, the field cancerization model did not include independent cellular origin of tumors. The leading idea behind intraepithelial migration is that individual tumor cells migrate and spread in the otherwise normal epithelium and subsequently form a new tumor at a distant site. Intraepithelial migration is expected to result in continuous areas of transformed cells. As the distance a neoplastic cell may migrate is limited, the intraepithelial migration predicts localized recurrences. Furthermore, the primary and the recurrent tumors are expected to show clonal relationships. The hypothesis of intraluminal seeding states that recurrent and multiple tumors arise from the shredding of cells from a primary tumor and that shred cells are implanted in the urothelium resulting in the growth of new tumors. It has been suggested that the inflammatory reaction and/or the wound healing response induced by tumor resection would facilitate the implantation and growth of seeded cells. As the shred cells are distributed in the bladder through the urine, recurrent tumors may be induced at some distance from the primary tumor. Hence, multiple tumors would show a clonal relationship but mucosa located between the tumors would not show the presence of neoplastic cells.
Premalignant lesions and normal urothelium show genetic changes found in cancer cells.
There is growing evidence for the presence of chromosomal and genetic changes characteristic of UCC already in premalignant lesions. Hartmann et al. [6] showed that 10 out of 14 hyperplasias showed monosomies or partial loss of chromosome 9. In seven out of eight patients with genetic alterations in the hyperplasias the genetic changes were also present in the concomitant papillary tumors. In two out of six investigated patients chromosome 9 deletions were also detected in biopsies of normal epithelium. The authors concluded that simple hyperplasia may be a precursor lesion for bladder cancer. Oberman et al. 2003 [7] showed by comparative genome hybridization (CGH) and LOH analyses that flat urothelial hyperplasia showed chromosomal imbalances shared by concomitant papillary tumors. The number of imbalances found in hyperplasias did not differ significantly from the numbers found in papillary tumors. In a similar analysis Chow et al. [8] found evidence for clonality with the concomitant papillary tumor in 10 out of 15 papillary hyperplasias using LOH. These findings were verified by fluorescent in situ hybridization (FISH) using probes for chromosome 9 which also detected losses of chromosome 9 in normal epithelium. In addition, the papillary hyperplasias also showed LOH at other chromosomal regions than seen in the tumors indicating that the genome had undergone a diversification already at the stage of hyperplasia. Hartman et al. [9] analyzed microdissected dysplasias and Tis (CIS) using FISH with probes for 9p, 9q, and 17p, LOH analyses of chromosome 9, and mutation analyses of TP53. Deletion of chromosome 9 was detected in 86% of the Tis and 75% of the dysplasias. Deletions of 17p at the TP53 loci were seen in 84% of the Tis and 53% of the dysplasias, and TP53 mutations were seen in 72 % of the Tis and 67% of the dysplasias. Due to the similar genetic profiles of dysplasia and Tis it was concluded that dysplasia is a precursor for carcinoma in situ.
As noted, the presence of cancer related mutations is not limited to pre-cancerous lesions but is also seen in morphologically normal urothelium in patients with UCC. Cianciulli et al. [10] showed by FISH analyses that morphologically normal urothelium from patients with UCC demonstrated genetic aberrations common to those of bladder cancer. Particularly -9 and +7 was seen in the tumors and the proximal as well as in the distal mucosa. Steidl et al. [11] showed by FISH analyzes that in 8 of 11 cases both the tumors and their adjacent urothelium were affected by chromosomal aberrations. In five of the eight cases at least one identical chromosomal aberration was observed in both the urothelium and the corresponding tumor suggesting a clonal relationship. In two of the cases the normal urothelium contained changes not seen in the adjacent tumor, demonstrating that karyoptypic evolution takes place within the normal urothelium. Genomic imbalances in normal urotheliun have also been shown by CGH and LOH [12] [13] [14] . Stoehr et al. [15] found LOH of chromosomes 9 and 8 in histologically normal epithelium in five out of fifteen patients. Thirty cases with no history of UCC were used as controls and no LOH was found.
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The genetic alterations seen in normal and premalignant cells are not limited to chromosomal changes but also include gene mutations and epigenetic changes. Pycha et al. [16] found TP53 to be overexpressed as determined by immunohistochemistry (IHC) in similar rates in both malignant and nonmalignant cells. Simon et al. [17] showed that normal mucosa adjacent to the tumors as well as the tumors showed positive IHC staining for TP53. The IHC staining was located in continuous areas and not scattered as would have been expected if intraluminal seeding had occurred. The authors conclude that their findings may be explained by intraepithelial migration. Stoehr et al. [18] showed that normal urothelium, preneoplastic lesions, as well as the tumors shared the same TP53 mutation and that regions of normal epithelial cells were TP53 positive by IHC. Muto et al. [13] showed that epigenetic changes, methylation, of the tumor suppressor gene CDKN2A also took place in normal mucosa. 
Recurrences, multifocal tumors, and the question of clonality
To investigate the possible multiclonality among multiple tumors from the same patient Sidransky et al. [19] analyzed 13 tumors from 4 different patients by chromosome X-inactivation analysis. In each case the tumors showed X-inactivating patterns consistent with a monoclonal origin. Li et al. [20] studied 10 patients with both synchronous and metachronous Ta/T1 tumors by X-chromosome inactivation analyses. Tumors from the same patient showed the same X-inactivation pattern indicating a mono-clonal origin in all investigated cases. Cheng et al. [21] studied 11 patients with muscle invasive UCC from which samples from different regions were taken. Nonrandom Xchromosome inactivation patterns were found in nine cases (82%), whereas two cases showed different patterns in different sites suggesting an oligoclonal origin.
Hartman et al. [22] Hafner et al. [26] investigated synchronous and metachronous tumors from patients with at least one upper urinary tract tumor using LOH and TP53 mutation analysis with the motivation that overgrowth by one clone or intra epithelial migration is unlikely when examining upper and lower urinary tract tumors. The pattern of deletions revealed monoclonality of all tumors in nine patients whereas five patients showed evidence for oligolonality. It was concluded that the patients with a monoclonal origin supported intra luminal seeding and that the patients with oligoclonal origin suggested the hypothesis of field effect cancerization.
Based on accumulated data one may conclude that the majority of multiple and recurrent tumors show monoclonality indicating a common cellular origin whereas only a minority show oligoclonality and independent origins. However, to establish "monoclonality" different means may be used [27] .
Demonstrating monoclonality using the X-inactivation pattern indicates that e.g., preneoplastic and neoplastic cells, originates from the same precursor cell but does not exclude the possibility that descendants of this precursor have accumulated different aberrations during tumor evolution. On the other hand, the term "clonality" may be used to indicate that the recurrent tumor derives from cells in a primary overt tumor e.g., by intraluminal seeding. In this case the absence of relatively late genetic changes e.g., a TP53 mutation or LOH of a given DNA marker, in a recurrence when present in a previous tumor, would indicate "oligoclonality" but would be inconclusive if referring to a common precursor cell. Hence, as divergent LOH patterns in meta-and synchronous tumors have been used as an argument for diverse cellular origins, the reported frequency of oligoclonality may be an overestimation of the actual incidence of oligoclonal progenitor cells.
Histologic-genetic mapping
Using X chromosome inactivation analysis of cells microdissected from histological slides from a normal female human bladder Tsai et al. [28] showed that the normal urothelium was organized in patches of monoclonal segments. These patches were about 120 mm 2 With the aim to characterize the extent and distribution of genetic and histological alterations in bladders from patients with UCC Chaturvedi et al. [29] and Czerniak et al. [30] superimposed histological and genetic maps from cystectomized bladders. This was accomplished by dividing the entire bladder mucosa into a large number of segments and by examining each segment both histologically and genetically. The segments were analyzed for chromosome aberrations using LOH of chromosome 17 and for mutations in TP53 [29] or by LOH of chromosome 9 and mutations in CDKN2A and CDKN2B [30] . LOH analyses revealed that for many markers the same allele was lost in all samples with LOH indicating a clonal relationship among samples. By superimposing the LOH data for specific markers over the histological maps two patterns were seen; a scattered pattern with preceded the development of microscopically identifiable urothelial abnormalities. In the study by
Chaturvedi et al. [29] , TP53 mutations were mapped to early stages of utothrelial neoplasia. One of the investigated cases showed three separate foci of tumors all exhibiting the same TP53 mutation. The same TP53 mutation was also seen in areas of intraurothelial precursor conditions separating the three foci. Czerniak et al. [30] showed the presence of homozygous deletions of the CDKN2A gene in morphologically normal mucosa. Furthermore, gradual expansion of the deleted region occurred in the progression to low grade and subsequently to high grade intraurothelial neoplasia, and in the transition to carcinoma. In an extended and analogous study Czerniak et al. [31] showed that LOH for chromosomes 4, 8, 9, 11, and 17 existed in the normal urothelium showing that extensive karyotypic evolution already occurs in morphologically normal cells, including changes that are associated with advanced tumors. Stoehr et al. [18] performed histological-genetic mapping of cystectomized bladders from patients with invasive tumor. TP53 mutations were detected in regions with preneoplastic lesions as well as in physiologically normal urothelium. In a similar way Simon et al. [17] showed that synchronous tumors with TP53 mutations were located within continuous areas of normal urotheliun with TP53 mutations, whereas tumors with wtTP53 were located within areas of urothelium showing no mutations.
Histologic and genetic mapping of bladders with UCC have thus shown that areas with LOH and gene mutations may cover large parts of the urothelium and that these regions are larger than the normal patches of monoclonal cells described by Tsai et al. [28] . In fact the genetically altered regions almost completely covered the inner surface of the bladder in some cases [29, 30] . This indicates that a massive intraepithelial spread of genetically altered cells has taken place. Some markers showed LOH in almost all of the mapped segments, indicating large clonal segments, whereas others were scattered and showed "islands" of LOH. This shows that the cells evolve locally during spreading, resulting in a genetically heterogeneous field of cells. The TP53 mutation mapping of cystectomized bladders demonstrates further that tumors are located in fields of normal/preneoplastic cells showing the same gene mutation as in the tumor proper (Figure 3) . The accumulated histologic-genetic mapping data thus favors intraepithleial migration and makes intraluminal seeding less likely as the most prominent mechanism for tumor spread or recurrence.
The chronology of tumor presentation does not parallel the genetic evolution
van Tilborg et al. [32] studied 11 patients with five or more recurrences using LOH and mutation analyses. For each patient tumor progression trees were constructed based on the accumulating number and sizes of the genetic changes, creating a chronology of the recurrences based on genetic events. By comparing the genetic chronology with the chronology of tumor appearance it was found that the genetic progression trees better reflected the tumor evolution than their chronologic order of presentation. In fact this was the leading principle rather than the exception. Hence, recurrences with more evolved genomes could appear long before clonally related recurrences with less evolved genomes. The suggested lack of correlation between the chronological appearance of tumors and genetic progression is also supported by the fact that recurring tumors may be of lower grade than the preceding ones. Borhan et al. [33] showed that grade regression occurred in almost 50% of the investigated cases and that only 33% of TP53 positive cases were positive at the recurrence. Data presented by Dahse et al. [34] supports that TP53 mutations present in a primary tumor may be absent in the recurrent tumor. Thus the chronology of tumor presentation does not reflect the genetic progression suggesting that cells or segments of the urothelium with differently progressed but clonally related genomes may co-exist and produce overt tumors independently.
Two phases of bladder cancer.
The data favoring the presence of genetic changes characteristic of frank carcinomas in morphologically normal urothelium, including LOH, chromosomal changes, and gene mutations, is more than convincing. The use of microdissection has successfully showed that premalignant lesions, [36] and recently cancer stem cells have been revealed in breast cancer [37] and in glioblastoma [38] . Self-renewing cancer cells may either derive from stem cells or from restricted progenitor or differentiated cells that acquire a self-renewal potential. A possible scenario could thus be that a self-renewing cell, of either origin, acquires genetic alterations that partly blocks differentiation, and then colonizes the patches described by Tsai et al. [28] . All cells in a patch will eventually become genetically altered daughter cells. As a result of subsequent genetic alterations successive cells escape normal growth control by neighboring cells and develop into expanding clones that invade adjacent patches and laterally displace the normal epithelium resulting in fields of premalignant cells [39] . Thus the spreading of premalignant cells would involve intraurothelial displacement, rather than intra epithelial migration, replacing the genetically normal epithelium. The outcome of this process would be a sheet of epithelial cells with cancer-associated genetic alterations, but without invasive or exophytic growth making it a histopathologically benign lesion.
The process of multistep carcinogenesis is most likely operating already during field extension as several chromosomal changes and gene mutations may be present in morphologically normal urothelium in patients with UCC. As a consequence of accumulated genetic changes, cells will eventually develop into frank carcinomas, the field-first-tumor-later model. It is conceivable that the likelihood for a transformation to occur is related to the number of acquired genetic aberrations; cells 11 with highly evolved genomes would be more liable to transform than cells with less evolved genomes.
However, as shown by van Tilborg et al. [32] the chance for a transformation event to occur does not seem to be related to karyotyopic complexity. No relationship between karyotypic evolution and the chronology of appearance is seen in patients with several recurrences [32] , suggesting that the transformation event is, at least to some extent, uncoupled to previous changes (Figure 4) . At the time of tumor presentation the urothelium most likely already is in a state of criticality, or "field cancerization", showing several genetically evolved and divergent segments of the urothelium. It could be envisaged that a transforming event, e.g., a profound increase in proliferation, in an individual cell in such a field may result in a local cancerous growth but leaving the neighboring cells in their respective states. In this scenario bladder cancer would not be a local disease but "a local manifestation of a diffuse abnormality of the urothelium" [40] . A corollary of the histologic-genetic mapping and several LOH, FISH, and CGH investigations of premalignant lesions is that karyotypic evolution appears to occur already in premalignant cells.
Furthermore, some level of chromosomal instability may have been acquired already before the transition to overt cancer. An indication of this is that premalignant and normal urothelium may show chromosomal changes associated with advanced and invasive tumors such as losses of 3p, 5q, 6q, 8p, 17p, and 18q [1, 6, 7, 8, 13, 29] . Clearly, cells with chromosomal changes associated with late and invasive stages may remain dormant in the sense that they do not produce frank tumors. Even though chromosomal changes alone may not be sufficient for cancerous growth, the accumulated evidence for an association between tumor stage and grade, and karyotype pattern is convincing [1, [41] [42] [43] [44] . This opens for the possibility that a local event initiating the "acute phase", apart from changing the growth properties of the cells, transforms the cells into tumor stages and grades determined by the genetic changes acquired during the "chronic phase" (Figure 4) . Consequently, when a recurrent tumor "progresses" to a higher grade or stage, cells in a different segment of altered urothelium, with a different set of genetic changes, may have been activated, and conversely in cases of tumor regression ( Figure 3) . Furthermore, this segment could have been present already at the presentation of the primary tumor. The activation of different segments of clonally related but diverged patches of cells could, at least to some extent, explain cases of grade regression [33] , that multiple tumors may show different grades, stages, or mutations [17, 45, 46] , and the lack of correlation between the chronology of presentation and genetic evolution [32] .
Consequences for treatment
The A promising method to evaluate the presence and extension of preneoplastic lesions is the use of fluorescent agents that specifically labels segments of hyperplasia and dysplasia but not normal urothelium [47] . This approach has led to the identification of affected segments of the urothelium not observed by normal cystoscopy. However, even if the use of fluorescent agents will lead to more complete resections, a combination with adjuvant chemotherapy to eradicate remaining hyperplastic/preneoplstic cells may be necessary. In this scenario the active agent has to discriminate between normal and hyperplastic/preneoplstic urothelium in order to avoid side effects caused by reactions in the normal urothelium; a none-trivial task given the similarity of normal and hyperplastic
cells. An alternative is to target genetic changes present in hyperplastic/preneoplstic but not in normal urothelium with chemotherapeutic agents, in analogy with the treatment of CML expressing the fusion gene BCR/ABL1 with Imatinib (Glivec) [48] . A possible target in UCC could be FGFR3 as this gene is mutated in about 70% of papillary tumors [49] and drugs specifically inactivating the corresponding protein have been described [50] . If, however, the field defect is a consequence of the activity of cancer stem cells, cancer stem cells should be the ultimate target for therapy. Thus a major future goal in the analysis of UCC is to identify and characterize possible bladder cancer stem cells. finally, within one of these areas a third genetic event has taken place resulting in a patch of cells with even more evolved genomes. These areas represent regions of "diffuse abnormalities" [40] . A primary overt tumor (T P ) has occurred in a field with two genetic changes, the first recurrence (T R1 ) in the field with one genetic change, and the second recurrence (T R2 ) in the field with three genetic changes.
Hence, in this case, the produced genetic tree would not coincide with the tree produced by the chronologic appearance [32] . An assumed starting point for the spreading of genetically aberrant cells by epithelial displacement is indicated by a filled square. 
